You just read:

CHMP Recommends Renewal of Translarna's™ Marketing Authorization for Nonsense Mutation Duchenne Muscular Dystrophy Based on Continued Positive Benefit-Risk Assessment

News provided by

PTC Therapeutics, Inc.

11 Nov, 2016, 07:15 ET